UBS Group AG - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS Group AG ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,513,310
-16.4%
90,726
+38.4%
0.00%0.0%
Q2 2023$1,810,215
-32.1%
65,540
-43.5%
0.00%0.0%
Q1 2023$2,666,597
+8.4%
115,939
-48.6%
0.00%0.0%
Q4 2022$2,460,521
+526.1%
225,529
+384.2%
0.00%
Q3 2022$393,000
-61.5%
46,580
-63.9%
0.00%
Q2 2022$1,020,000
-64.9%
128,987
+5.1%
0.00%
-100.0%
Q1 2022$2,907,000
+28.2%
122,765
+85.1%
0.00%0.0%
Q4 2021$2,268,000
+85.0%
66,311
-4.2%
0.00%
Q3 2021$1,226,000
+921.7%
69,215
+2491.4%
0.00%
Q2 2021$120,000
-89.6%
2,671
-94.0%
0.00%
Q1 2021$1,154,000
-11.8%
44,573
-31.4%
0.00%
Q4 2020$1,309,000
+22.9%
64,933
+19.2%
0.00%
Q3 2020$1,065,000
-12.2%
54,488
-20.7%
0.00%
-100.0%
Q2 2020$1,213,000
+134.6%
68,687
-6.2%
0.00%
Q1 2020$517,000
+247.0%
73,233
+246.1%
0.00%
Q4 2019$149,000
-25.5%
21,159
+27.3%
0.00%
Q3 2019$200,000
-84.2%
16,619
-84.1%
0.00%
Q2 2019$1,262,000
+5909.5%
104,201
+6234.4%
0.00%
Q1 2019$21,000
+75.0%
1,645
-11.7%
0.00%
Q4 2018$12,000
-83.6%
1,863
-73.6%
0.00%
Q3 2018$73,000
-73.6%
7,055
-82.8%
0.00%
Q2 2018$276,000
+3350.0%
41,001
+10467.3%
0.00%
Q4 2017$8,000
+60.0%
388
+25.6%
0.00%
Q3 2017$5,000
-73.7%
309
-81.5%
0.00%
Q2 2017$19,000
+375.0%
1,671
+407.9%
0.00%
Q1 2017$4,000
-87.5%
329
-77.2%
0.00%
Q4 2016$32,000
+39.1%
1,443
+35.0%
0.00%
Q3 2016$23,0001,0690.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$56,331,20918.32%
Kynam Capital Management, LP 1,375,000$31,625,0004.08%
BVF INC/IL 3,775,900$86,845,7003.18%
Cormorant Asset Management, LP 1,700,000$39,1002.58%
RTW INVESTMENTS, LP 4,600,799$105,818,3772.20%
Ghost Tree Capital, LLC 225,000$5,175,0001.53%
683 Capital Management, LLC 791,000$18,193,0001.36%
Ikarian Capital, LLC 211,400$4,862,2001.10%
Ikarian Capital, LLC 211,400$4,862,2001.10%
SILVERARC CAPITAL MANAGEMENT, LLC 105,486$2,426,1781.00%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders